Money Matters, Simplified.
What Investors Think About Lannett
Thu, 07/22/2010 - 00:24 by Motley Fool
Together, we are all trying to build our fortune by finding well-run companies at bargain-basement prices. But it takes work -- scouring company earnings reports, scrutinizing key data, and assessing the competition.
Because of that, we've created a screen based on the massive data aggregated from the more than 165,000 investors competing on our Motley Fool CAPS platform. Each quarter, we check in on select companies after they file a 10-Q and track community sentiment -- so you can see how your company is doing. Here's the community sentiment on Lannett (AMEX: LCI)both this quarter and last (for comparison), as well as opinions on some related companies. Source: Motley Fool CAPS. Dates given are the posting dates of Lannett's most recent quarterly and/or annual reports to the SEC's website. Percentages are calculated from the number of members rating each company. A change in the community's approval (signified by four- and five-star ratings) or disapproval (one- and two-star ratings) could indicate that further research is in order. To help make your research easier … © 2010 UCLICK L.L.CMetric Lannett Optimer Pharmaceuticals(Nasdaq: OPTR) STADA Arzneimittel(Nasdaq:STDAF.PK) Alexza Pharmaceuticals(Nasdaq: ALXA) This Quarter (5/13/2010): Price: $4.83 $11.47 $39.60 $3.75 % of Members Rating Outperform 83% 70% 50% 89% % of All-Star Members Rating Outperform 84% 75% 100% 91% CAPS Rating (out of 5) ** ** *** Last Quarter (2/12/2010): Price: $4.17 $11.93 $34.55 $2.80 % of Members Rating Outperform 73% 71% 50% 87% % of All-Star Members Rating Outperform 63% 67% 100% 87% CAPS Rating (out of 5) * ** ***
